MILWAUKEE, Wis., Oct. 29, 2018 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical companydeveloping innovative therapies for neuropsychiatric disorders, announced today that Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023, a novel activator of System
This presentation is scheduled for:Date: Wednesday, November 7, 2018 Title: SXC-2023, a Potential Therapeutic for Various CNS Disorders, is Safe and Well-Tolerated in Phase 1 Clinical StudiesPoster Number: 684.06
About Promentis Pharmaceuticals Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders. Promentis' drug development efforts are focused on a unique approach to address imbalances in glutamatergic neurotransmission and oxidative stress. The Company's first indication is trichotillomania, a highly prevalent disorder for which there is no approved therapy, and for which there are no other known treatments in development. For more information regarding trichotillomania, see http://www.promentispharma.com/technology/trichotillomania/
For further information, please contact:Promentis PharmaceuticalsChad E. Beyer, PhD(e) email@example.com
Media Contact:Tiberend Strategic Advisors, Inc.Janine McCargo(t) 646-604-5150(e) firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/promentis-pharmaceuticals-to-present-at-the-society-for-neuroscience-conference-300739038.html
SOURCE Promentis Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!